INTRODUCTION AND OBJECTIVES:
The lack of non-invasive diagnostic tests capable to distinguish between indolent and aggressive prostate cancer (PCa) may lead to over-diagnosis and overtreatment. Although multiparametric MRI (mpMRI) has shown high NPV for the detection of clinically significant PCa (csPCa), it is still limited by suboptimal specificity and sensitivity for small lesions. Since prostate has exhibited unique metabolite profile, we hypothesized that a urinemetabolomic signature can be developed in order to improve predictions of csPCa at initial prostate biopsy (PB).
METHODS: Overall, the study evaluated the expressed prostatic secretions (EPS)-urine obtained after DRE in 238 patients. Our approach consisted of three different steps. First, in order to identify a specific metabolomic signature predictive of csPCa (GS>[7), we performed an untargeted metabolomics study (C18 and BEH Amide) tandem mass spectrometry in 100 patients affected by either histologically-proven BPH (n[50) or csPCa at radical prostatectomy (n[50). EPS-urine were collected the day before surgery. Second, an initial validation was made in 46 consecutive unselected patients scheduled for initial PB without prior mp-MRI. The discrimination accuracy of our multivariable model to detect csPCa was quantified using the AUC method. Third, we further validated the prediction ability of our signature in a new cohort of 92 subjects receiving mp-MRI and scheduled for MRI-targeted and concomitant systematic PB. A set randomized experiments were performed to assess the capability of Neural Network models to predict csPCa using the metabolite concentrations and the results of mpMRI as feature input variables RESULTS: Overall, we identified 48 metabolites more frequent in men with csPCa versus BPH (all p <0.01). After 4 normalization methods, only 3 metabolites (3-Phosphoglyceric acid, aminoadipic acid and quinolinic acid) were included in our signature.In the first validation cohort, the metabolomic signature had a substantially higher AUC in predicting csPCa as compared to clinical parameters (0.753 vs.0.64, respectively; p<0.001). Decision curve analyses showed a higher net benefit for the model including the level of the three selected metabolites as compared to the base model. In the mp-MRI validation study, a Neural Network prediction model revealed an higher accuracy rate of EPS-Metabolomic signature combined with mpMRI to predict csPCa when compared with the metabolic signature alone (81% vs 74%, respectively; p<0.001) CONCLUSIONS: We developed and internally validated a novel metabolomic signature significantly associated with csPCa. The addition of our novel EPS-Metabolomic Test was able to improve the accuracy of mpMRI in predicting the presence of csPCa at biopsy. While waiting for external validation, this metabolomic signature seems to represent a promising tool to better tailor biopsy indications according to each patient profile 
